WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™Collaboration is a three-year and potentially multi-TCR program partnershipView original content:https://www.prnewswire.co.uk/news-releases/wuxi-biologics-and-medigene-enter-into-a-research-collaboration-for-off-the-shelf-tcr-guided-t-cell-engagers-302217383.html

en | CA7609751028 | WUXI | boerse | 67928044 |